When blood is not an option.
DID YOU KNOW?
Hemorrhage is the leading cause of trauma-related death in both civilian and military populations.
OUR FOCUS
We’re reshaping the modern blood replacement protocols and striving to save more lives.
Innovative
science
EXPERIENCED
LEADERSHIP
OUR PRODUCT
OxyBridge™
Supercharged oxygen delivery
Human-derived, hemoglobin-based
We’ve developed a ready-to-use oxygen-carrying plasma expander to restore circulatory system parameters.
With $5.6 million in non-dilutive grants from the Department of Defense, we’re investigating the product’s use as a pre-hospital, low-volume, oxygen-delivering resuscitation fluid in humans.
Administered like blood (IV)
Safe
Virus free and sterile
Easy to use
Universally compatible
Can be stockpiled
Multi-year room temperature stable
Increases bloodstream oxygen
Improves oxygen uptake through the lungs
breaks reliance on the cold chain
Indicated for Blood Loss
- Delivers oxygen
- Maintains blood pressure
- Improves coagulation when combined with plasma
- Not refrigerated, can be used out of hospitals
- Used pre-hospital as a low volume resuscitation fluid during hemorrhage when blood is not an option
- Estimated $11 billion annual market
Indicated for Emergencies
- Stockpiled for emergency preparedness use during catastrophic events where the blood supply is interrupted or contaminated
- Estimated $600 million annual market
Indicated for Lung Dysfunction
-
Delivered i.v., independent of ventilator use
- Increases uptake through lungs
- Oxygen delivered to reduce flow regions
- May prevent need to go on ventilator
- Used as an adjunct to circulating Red Blood Cells (RBC’s) to increase oxygen uptake and release during conditions of hypoxia due to lung damage or vasculature occlusions (e.g COVID-19)
- Market Developing
Indicated for Organ Transplantation
- Use of the system will help preserve organs longer, increase utilization, and improve transplant outcomes
- Teamed with Organ Assist to provide a complete system for ex vivo organ maintenance
- Used as an oxygen-delivering perfusate in an organ perfusion system (partnering with OrganAssist – Netherlands) to improve outcomes of organ transplants
- Estimated $500 million annual market
OUR TEAM
Joseph Tucker, PhD
Chief Executive Officer
- Co-founded four biotechnology companies, took two public
- Raised more than $50MM Shepherded five drugs in clinical trials
Phil Farabaugh
Vice President, Operations
- 10+ years of operations and financial roles related to commercial strategy, corporate compliance and contract management
- $6.5M in grants including NIH, SOCOM and DOD
W. Richard Light, PhD
Chief Scientific Officer
- 30 + years in biologic drug development through all aspects including commercialization
- $7MM in grants and over 12 patents
Kim Vandergriff, PhD
Vice President, Research & Development
- Co-authored 30+ years leading R&D teams in drug development in Military, Academic, and Industry Laboratories
- Over 50 peer-reviewed publications and several patents
COL (Ret) Dallas Hack, MD, MPH
Director, Medical Affairs
- Former Multinational Force Iraq Command Surgeon
- Director, Combat Casualty Care, Chair of Joint Program Committee 6, 2008-2014
Andrew Wright
Vice President, Marketing
- 30+ years of experience of business development, sales, marketing, and senior management experience
- He was most recently COO of the Hodgdon Group
Contact us
Email Us
info@virtechbio.com
Media Inquiries
pffarabaugh@virtechbio.com
Our Location
27 Strathmore Road
Natick, MA 01760
U.S.A.